Babraham Bioscience Technologies Limited
Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
|Address:||Babraham Research Campus, Babraham, Cambridge|
Acknowledged as a leading research and innovation campus for the UK, home to both world-class academic research and commercial biomedical companies, the Babraham Research Campus has established itself as a hub of bioscience innovation at the heart of the Cambridge cluster.
Babraham offers an innovative community, a dynamic co-location of academic research from the world-class Babraham Institute, with commercial organisations on the campus developing bioscience therapies and technologies to treat human disease. The campus’ role is to support bio-enterprises, both for organisations located at the campus, but also with the wider Cambridge cluster, including our relationship with Pfizer, Medimmune, Cambridge University, Cambridge Enterprise and One Nucleus.
At the cornerstone of the campus is the internationally-regarded Babraham Institute, which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The Institute’s research is focussed on generating new knowledge of the biological mechanisms underlying ageing, development and the maintenance of health. The Institute also aims to promote knowledge exchange between academia and industry and to initiate partnerships to translate innovative science into viable ventures.
Babraham Bioscience Technologies (BBT) has successfully developed and managed the campus infrastructure over the last 15 years; central to this are Babraham’s Bioincubator buildings (total offering is 130,000 sq ft of lettable area), which offer serviced facilities, on attractive, flexible terms, to support new bio-ventures and catalyse the commercial exploitation of biomedical research.
In the 2011 Budget the Chancellor announced a £44M investment in the Babraham Research Campus. The first part of the development plan funded by the £44M investment has been the construction of Babraham’s fifth Bioincubator Building – Moneta offering 17,000 sq ft of laboratory and office accommodation. Continuing the campus developments, the newly completed Jonas Webb Building offers around 16,000 sq ft of lettable space, which includes fume hoods, open plan bench space, offices and meeting rooms.
Development to the north of the Campus continues with construction of The Bennett Building well underway. The building will offer 20,000ft2 of follow-on molecular biology laboratory and office space for up to 6 tenants and will be available to occupy from November 2014.
Accelerating Innovation in the Technology Development Laboratory (TDL)
Another offering at the Babraham campus is the Technology Development Laboratory (TDL), established by BBT to provide access to resources, equipment and space so that early-stage concepts can be developed to commercially-viable opportunities. Companies and entrepreneurs can hire individual bench spaces in fully equipped laboratories on a flexible basis. The TDL’s scientific staff offer bespoke, state-of-the-art R&D services and scientific assistance across many fields including molecular biology, protein biochemistry, cell biology, immunology, medicinal and synthetic chemistry. The services of the TDL are available to campus companies, academic scientists and also external biomedical companies.
Babraham’s TDL has a relationship with The University of Cambridge’s ideaSpace to offer a more connected support mechanism for early-stage companies to help to accelerate enterprise in the region. Ventures have dual access to the ‘plug and play’ laboratory facilities in Babraham’s TDL and the co-working community at the ideaSpace in the Hauser Forum. Many companies don’t need full time access to lab facilities but want to access it on an ‘as needed’ basis. The superb facilities at Babraham can help ideaSpace support a wider range of members from different sectors who require such specialist facilities.
Each year BBT seeks to encourage and enhance bioscience investment through presentation and networking opportunities for early-stage biotechnology and med tech companies and investors at the Biotechnology Investment Forum (BIF).
Access to world-class scientific facilities
Companies located on the Babraham Research Campus also have access to the Babraham Institute’s world-class scientific facilities. These facilities include bioinformatics, imaging, mass spectrometry (including lipid analysis), next generation sequencing and flow cytometry. The campus also has a world-class small animal facility which is available for use by tenant companies.
A new bio-incubator and life science accelerator capability has been launched at the Babraham Research Campus. Accelerate@Babraham is supported by AstraZeneca, MedImmune, One Nucleus, and RxCelerate.
25 January 2018Read in full
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.
8 January 2018Read in full
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited, (BBT) the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).
5 January 2018Read in full
Mission Therapeutics, a Babraham-based drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
27 June 2017Read in full
Madrid, Spain, Heidelberg, Germany, and Cambridge, UK...Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.
26 June 2017Read in full
Held at The Babraham Research Campus, the annual Babraham Investor Conference (BIC) gave scale-up and venture-stage growth companies seeking Seed to Series C funding, the opportunity to showcase their science to investors actively seeking further investment opportunities.
26 May 2017Read in full
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced it has added ALEXA Fluor® 488, one of the most popular fluorescent labels used by life science researchers, to its Lightning-Link® range of antibody and protein labeling kits.
4 May 2017Read in full
Today, the Biotechnology and Biological Sciences Research Council (BBSRC), Babraham Bioscience Technologies Ltd (BBT) and BioMed Realty, a Blackstone portfolio company, have announced a partnership that will see BioMed Realty signing a long-term lease on approximately eight acres of BBSRC-owned land at the Babraham Research Campus, Cambridge. The investment will enable the ground-up construction of two new buildings for growing bioscience-based companies at the campus.
19 April 2017Read in full
On World Parkinson’s day today, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J Fox Foundation for Parkinson’s Research (MJFF).
11 April 2017Read in full
22 May 2018The Cambridge Building, Babraham Research Campus
A must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe, seeking Seed to Series C funding.